SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 519.63 |
| Enterprise Value ($M) | 531.12 |
| Book Value ($M) | 171.45 |
| Book Value / Share | 0.99 |
| Price / Book | 3.03 |
| NCAV ($M) | 160.71 |
| NCAV / Share | 0.93 |
| Price / NCAV | 3.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.48 |
| Return on Assets (ROA) | -0.61 |
| Return on Equity (ROE) | -0.79 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.73 |
| Current Ratio | 13.73 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 202.13 |
| Assets | 212.88 |
| Liabilities | 41.43 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -103.20 |
| Net Income | -95.88 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -89.09 |
| Cash from Investing | -39.94 |
| Cash from Financing | 117.58 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Bain Capital Life Sciences Fund II, L.P. | 9.99 | 20.84 | |
| 13G | Vestal Point Capital, LP | 6.30 | ||
| 13G/A | Farallon Capital Partners, L.P. | 9.99 | 2.96 | |
| 13G/A | Wellington Management Group Llp | 3.20 | -36.44 | |
| 13G | Frazier Life Sciences Public Fund, L.P. | 5.00 | ||
| 13G/A | Prudential Financial Inc | 4.50 | -24.29 | |
| 13G/A | Adage Capital Management, L.P. | 4.10 | ||
| 13G/A | Jennison Associates Llc | 4.10 | -23.62 | |
| 13G | BlackRock, Inc. | 5.70 | 0.00 | |
| 13D/A | Growth Equity Opportunities 17, LLC | 14.90 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 168,007 | 727,157 | 23.10 | |
| 148,723 | 737,882 | 20.16 | |
| 240,941 | 924,063 | 26.07 | |
| 360,640 | 1,191,688 | 30.26 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SRRK – Scholar Rock Holding Corporation | STOK – Stoke Therapeutics, Inc. |
| STTK – Shattuck Labs, Inc. | SWTX – SpringWorks Therapeutics, Inc. |
| SYRE – Spyre Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io